A phase I study of hyperfractionated low-dose radiotherapy (RT) as a chemotherapy sensitizer in combination with gemcitabine (G) and erlobtinib (E) in advanced pancreatic cancer.
Andre A. Konski
Research Funding - Genentech
Joshua E. Meyer
No relevant relationships to disclose
Philip Agop Philip
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Anthony Frank Shields
No relevant relationships to disclose
Michael J. Hall
No relevant relationships to disclose
Minsig Choi
No relevant relationships to disclose
Gail Duncan
No relevant relationships to disclose
Beth Adaire
No relevant relationships to disclose
Erin McSpadden
No relevant relationships to disclose
Steven J. Cohen
Honoraria - Genentech